Barclays
ICCC icon

Barclays’s ImmuCell ICCC Stock Holding History

Barclays’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7
Closed -$44 – 5427
2025
Q3 		$44 Buy
+7
New +$44 ﹤0.01% 5322

Other funds holding ICCC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's ICCC Position: Q4 2025 in Review

Barclays sold out of ImmuCell (ICCC) in Q4 2025, closing a stake of 7 shares — an estimated $44 sold.

Barclays first reported a position in ICCC in Q3 2025 and held it in 1 quarter. The position peaked at $44 in Q3 2025. 26 funds tracked by Wall St. Rank hold ICCC as of Q4 2025.

  • Barclays reported no remaining ImmuCell position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 7 ImmuCell shares in Q4 2025, an estimated $44.
  • Barclays first reported a position in ImmuCell in Q3 2025 and held it in 1 quarter.
  • Barclays's ImmuCell position peaked at $44 in Q3 2025.
  • 26 funds tracked by Wall St. Rank held ImmuCell as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.